340 related articles for article (PubMed ID: 9708845)
1. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.
Solanto MV
Behav Brain Res; 1998 Jul; 94(1):127-52. PubMed ID: 9708845
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
Lurie S; O'Quinn A
J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
[TBL] [Abstract][Full Text] [Related]
3. Stimulant drug action in attention deficit hyperactivity disorder (ADHD): inference of neurophysiological mechanisms via quantitative modelling.
Rowe DL; Robinson PA; Gordon E
Clin Neurophysiol; 2005 Feb; 116(2):324-35. PubMed ID: 15661111
[TBL] [Abstract][Full Text] [Related]
4. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
Kollins SH
J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
[TBL] [Abstract][Full Text] [Related]
5. Treatment of attention-deficit/hyperactivity disorder.
Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
[TBL] [Abstract][Full Text] [Related]
6. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
Stevenson RD; Wolraich ML
Pediatr Clin North Am; 1989 Oct; 36(5):1183-97. PubMed ID: 2677938
[TBL] [Abstract][Full Text] [Related]
7. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
8. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies.
Spencer TJ; Brown A; Seidman LJ; Valera EM; Makris N; Lomedico A; Faraone SV; Biederman J
J Clin Psychiatry; 2013 Sep; 74(9):902-17. PubMed ID: 24107764
[TBL] [Abstract][Full Text] [Related]
9. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder.
Teicher MH; Polcari A; Anderson CM; Andersen SL; Lowen SB; Navalta CP
J Child Adolesc Psychopharmacol; 2003; 13(1):41-51. PubMed ID: 12804125
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacotherapy of attention deficit hyperactivity disorder.
Reddy DS
Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
[TBL] [Abstract][Full Text] [Related]
11. Attention deficit hyperactivity disorder in children.
Ramchandani P; Joughin C; Zwi M
Clin Evid; 2002 Dec; (8):280-90. PubMed ID: 12603883
[No Abstract] [Full Text] [Related]
12. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
[TBL] [Abstract][Full Text] [Related]
13. Attention deficit hyperactivity disorder in children.
Ramchandani P; Joughin C; Zwi M
Clin Evid; 2002 Jun; (7):262-71. PubMed ID: 12230649
[No Abstract] [Full Text] [Related]
14. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
15. Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action.
Ruskin DN; Bergstrom DA; Shenker A; Freeman LE; Baek D; Walters JR
Biol Psychiatry; 2001 Feb; 49(4):340-50. PubMed ID: 11239905
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder.
Schrantee A; Bouziane C; Bron EE; Klein S; Bottelier MA; Kooij JJS; Rombouts SARB; Reneman L
Brain Imaging Behav; 2018 Apr; 12(2):402-410. PubMed ID: 28321605
[TBL] [Abstract][Full Text] [Related]
17. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
[TBL] [Abstract][Full Text] [Related]
18. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
Gerlach M; Grünblatt E; Lange KW
Atten Defic Hyperact Disord; 2013 Jun; 5(2):71-81. PubMed ID: 23605387
[TBL] [Abstract][Full Text] [Related]
19. Managing stimulant medication for attention-deficit/hyperactivity disorder.
Wender EH
Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
[No Abstract] [Full Text] [Related]
20. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
Fone KC; Nutt DJ
Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
